Float Short %

9.57

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

3.45

EPS Last/This Y

1.88

EPS This/Next Y

-9.39

Price

6.91

Target Price

13.33

Analyst Recom

2.6

Performance Q

-58.61

Relative Volume

2.39

Beta

2.64

Ticker: MCRB

23 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	MCRB	0.6633	0.05	0.00	12280
2025-04-15	MCRB	0.464	0.05	0.03	12334
2025-04-16	MCRB	0.397	0.05	0.00	12316
2025-04-17	MCRB	0.37	0.05	0.77	12217
2025-04-18	MCRB	0.37	0.05	0.66	12217
2025-04-21	MCRB	0.3749	0.06	0.00	6410
2025-04-22	MCRB	8.24	0.06	0.00	6614
2025-04-23	MCRB	9.78	0.06	0.14	6599
2025-04-24	MCRB	9.11	0.06	0.00	6495
2025-04-25	MCRB	10.08	0.060670482420278	0	6486
2025-04-28	MCRB	9.31	0.060492418066199	0.090909090909091	6504
2025-04-29	MCRB	9.43	0.06	0.00	6514
2025-04-30	MCRB	9.74	0.06	0.00	6515
2025-05-01	MCRB	9.5	0.06	0.00	6517
2025-05-02	MCRB	9.66	0.06	0.00	6523
2025-05-05	MCRB	9.29	0.06	0.00	6525
2025-05-06	MCRB	8.63	0.06	0.00	6525
2025-05-07	MCRB	8.27	0.06	0.00	6525
2025-05-08	MCRB	6.98	0.06	6.00	6521
2025-05-09	MCRB	7.02	0.06	999.99	6523
2025-05-12	MCRB	7.88	0.06	999.99	6523
2025-05-13	MCRB	7.42	0.06	0.00	6524
2025-05-14	MCRB	6.82	0.06	0.00	6528
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	MCRB	0.66	129.6	-	-0.06
2025-04-15	MCRB	0.46	129.6	-	-0.06
2025-04-16	MCRB	0.40	129.6	-	-0.06
2025-04-17	MCRB	0.37	129.6	-	-0.06
2025-04-18	MCRB	0.37	129.6	-	-0.06
2025-04-21	MCRB	0.37	129.6	-	-0.06
2025-04-22	MCRB	8.16	129.6	-	-0.06
2025-04-23	MCRB	9.73	129.6	-	-0.06
2025-04-24	MCRB	9.11	129.6	-	-0.06
2025-04-25	MCRB	10.08	129.6	-	-1.25
2025-04-28	MCRB	9.31	136.5	-	-1.25
2025-04-29	MCRB	9.40	136.5	-	-1.25
2025-04-30	MCRB	9.70	136.5	-	-1.25
2025-05-01	MCRB	9.50	136.5	-	-1.25
2025-05-02	MCRB	9.63	136.5	-	-1.25
2025-05-05	MCRB	9.23	136.5	-	-1.25
2025-05-06	MCRB	8.61	136.5	-	-1.25
2025-05-07	MCRB	8.29	136.5	-	-1.25
2025-05-08	MCRB	6.93	136.5	-	-1.25
2025-05-09	MCRB	7.01	136.5	-	1.88
2025-05-12	MCRB	7.88	136.5	-	1.88
2025-05-13	MCRB	7.37	55.7	-	1.88
2025-05-14	MCRB	6.91	55.7	-	1.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

23 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	MCRB	-0.13	-0.79	12.56
2025-04-15	MCRB	-0.13	-0.79	12.56
2025-04-16	MCRB	-0.13	-0.79	12.56
2025-04-17	MCRB	-0.13	-0.79	12.56
2025-04-18	MCRB	-0.13	-0.79	12.56
2025-04-21	MCRB	-0.13	-1.08	12.56
2025-04-22	MCRB	-0.13	-1.08	12.56
2025-04-23	MCRB	-2.46	-1.08	12.56
2025-04-24	MCRB	-2.46	-1.08	12.57
2025-04-25	MCRB	-2.46	-1.08	12.57
2025-04-28	MCRB	-2.46	0	11.98
2025-04-29	MCRB	-2.46	0	11.98
2025-04-30	MCRB	-1.46	0	11.98
2025-05-01	MCRB	-1.46	0	11.98
2025-05-02	MCRB	-1.46	0	11.98
2025-05-05	MCRB	-1.46	0	11.98
2025-05-06	MCRB	-1.46	0	11.98
2025-05-07	MCRB	-1.46	0	11.98
2025-05-08	MCRB	-1.46	0	11.98
2025-05-09	MCRB	-1.46	0	11.98
2025-05-12	MCRB	-1.46	0	9.57
2025-05-13	MCRB	-1.46	0	9.57
2025-05-14	MCRB	-1.46	0	9.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

23 items 1 of 1

Last Quarter Act. EPS

-2.24

Avg. EPS Est. Current Quarter

-1.95

Avg. EPS Est. Next Quarter

1.21

Insider Transactions

-1.46

Institutional Transactions

Beta

2.64

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.1

Max Drawdown 5-Year %

-99.1

Target Price

13.33

P/E

Forward P/E

PEG

P/S

P/B

1.17

P/Free Cash Flow

EPS

-9.99

Average EPS Est. Cur. Y

1.88

EPS Next Y. (Est.)

-7.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.39

Return on Equity vs Sector %

120.9

Return on Equity vs Industry %

137.7

EPS 1 7Days Diff

3.1

EPS 1 30Days Diff

3.13

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y